Product Description: Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Rahman I, et al. L-selectin regulates human neutrophil transendothelial migration. J Cell Sci. 2021 Feb 8;134(3):jcs250340. /[2]Co MS, et al. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology. 1999 Mar;4(3-4):253-66. /[3]Seekamp A, et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial. Crit Care Med. 2004 Oct;32(10):2021-8.
CAS Number: 395639-53-9
Molecular Weight: N/A
Compound Purity: 99.76
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others